# PMN catalysts: ProMIS Neurosciences Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pmn/catalysts

> ProMIS Neurosciences Inc. (PMN) has 2 upcoming catalysts. The next is the ProMIS Neurosciences Inc. topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PMN?

ProMIS Neurosciences Inc. (PMN) has 2 upcoming catalysts. The next is the ProMIS Neurosciences Inc. topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Topline data expected in Q1 2027" [Calendar and source filings](https://sec-api.dev/companies/pmn/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125896, https://www.sec.gov/Archives/edgar/data/1374339/000110465926125896/pmn-ex99d1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/pmn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ProMIS Neurosciences Inc. |
| Ticker | PMN (Nasdaq) |
| SEC CIK | 1374339 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/pmn |

## Cash runway

Cash $44.1M as of 2026-09-30; quarterly burn $9.4M; about 14.1 months of runway at that rate (XBRL company facts, accession 0001104659-26-126263).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| late 2024 | [PMN310 trial start](https://sec-api.dev/pdufa/pmn310) | PMN | Alzheimer's disease | scheduled | "On track to initiate Phase 1b clinical trial in patients with Alzheimer's disease by end of 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114xex99d1.htm)) |
| November 14, 2024 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114xex99d1.htm)) |
| December 31, 2024 | [PMN310 trial start](https://sec-api.dev/pdufa/pmn310) | PMN |  | completed | "This increase is primarily attributable to a $3.5 million increase in spending on our lead program, PMN310, as we completed our Phase 1a clinical trial of PMN310 and initiated the Phase 1b clinical trial of PMN310 during the year ended December 31, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1374339/000155837025004068/pmn-20241231x10k.htm)) |
| March 31, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331xex99d1.htm)) |
| May 12, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512xex99d1.htm)) |
| August 13, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813xex99d1.htm)) |
| November 12, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112xex99d1.htm)) |
| 1H 2026 | [ProMIS Neurosciences Inc. interim data readout](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | scheduled | "ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results anticipated by the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512xex99d1.htm)) |
| March 25, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325xex99d1.htm)) |
| mid-2026 | [PMN310 topline data readout](https://sec-api.dev/pdufa/pmn310) | PMN |  | scheduled | "We believe we remain on track to report blinded top-line data in mid-2026 and 12-month top-line data toward the end of 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129xex99d1.htm)) |
| Q2 2026 | [PMN310 interim data readout](https://sec-api.dev/pdufa/pmn310) | PMN |  | scheduled | "On track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112xex99d1.htm)) |
| May 12, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm)) |
| Q3 2026 | [PMN310 interim data readout](https://sec-api.dev/pdufa/pmn310) | PMN |  | scheduled | "Near-term data catalysts, including the blinded 6-month interim analysis, are anticipated in early Q3 2026, and could provide important insight into the potential of our lead drug candidate, PMN310." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm)) |
| August 13, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813xex99d1.htm)) |
| late 2026 | [ProMIS Neurosciences Inc. topline data readout](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | scheduled | "Topline Results Anticipated by end of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512xex99d1.htm)) |
| November 12, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926126260/pmn-ex99d1.htm)) |
| Q1 2027 | [ProMIS Neurosciences Inc. topline data readout](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | scheduled | "Topline data expected in Q1 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926125896/pmn-ex99d1.htm)) |
| Q1 2027 | [PMN310 topline data readout](https://sec-api.dev/pdufa/pmn310) | PMN | early AD | scheduled | "On July 28, 2026, reported positive blinded six-month interim safety and biomarker results from the PRECISE-AD Phase 1b study of PMN310, showing no ARIA-E across all genotypes in a population that included 61% APOE4 carriers (of which 11% were homozygotes), ARIA-H of 4.4% (all mild and asymptomatic), no treatment-related SAEs and no drug-related discontinuations, and early biomarker movement consistent with target engagement; unblinded 12-month topline data are expected in the first quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1374339/000110465926126263/pmn-20260930x10q.htm)) |

## Drugs

- [PMN310](https://sec-api.dev/pdufa/pmn310): early ad, alzheimer's disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pmn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PMN catalysts: ProMIS Neurosciences Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pmn/catalysts

```bibtex
@misc{secapidev_companies_pmn_catalysts_20261116,
  title        = {PMN catalysts: ProMIS Neurosciences Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pmn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pmn_catalysts_20261116","title":"PMN catalysts: ProMIS Neurosciences Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pmn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
